



XBiotech Added to the MSCI US Small Cap 1750 and the MSCI Investable Market 2500 Indexes

November 20, 2015

AUSTIN, Texas, Nov. 20, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), the world's leading developer of True Human™ therapeutic antibodies, announced today that the Company is being added to the MSCI US Small Cap 1750 and the MSCI Investable Market 2500 Indexes as part of the November 2015 Semi-Annual Index Review for the MSCI Equity Indexes. All changes will be implemented as of market close on November 30, 2015. These changes have been posted on the Index Review web page on MSCI's web site at <https://www.msci.com/index-review>.

John Simard, CEO of XBiotech, stated, "XBiotech's addition to the MSCI US Small Cap 1750 and the MSCI Investable Market 2500 Indexes should serve to increase our exposure among investors and add value for our shareholders. Inclusion in key indexes such as MSCI offers an important, objective measure for investment interest in our company."

Membership in the MSCI Indexes means automatic inclusion in the appropriate growth and value style indexes. MSCI offers more than 160,000 indexes, which are used by investors around the world to develop and benchmark their global equity portfolios. It is estimated that more than USD 9.5 trillion in assets are benchmarked against MSCI indexes on a worldwide basis. MSCI's indexes are also licensed as the basis for financial products such as exchange traded funds (ETFs) and structured products. More than 750 ETFs from many of the world's leading ETF providers are based on MSCI's indexes, and it is estimated that USD 435 billion in ETF assets are based on their indexes globally.

For more information, visit us at www.msci.com.

About XBiotech

XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company's mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases. XBiotech's lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1 α), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech's True Human antibodies are cloned directly from individual donors who possess natural immunity against certain diseases.

Contacts:

Ashley Otero
Director of Investor Relations
XBiotech
aotero@xbiotech.com
512.386.2930

[Tiberend Strategic Advisors, Inc.](#):

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com

[XBiotech logo](#)

XBiotech